AbbVie, Parkinson's disease
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug showed significant improvements in patient symptoms, meeting primary and secondary endpoints.
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...
Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...
These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...
Maggie Smith, acting legend of 'Harry Potter' and 'Downton Abbey' fame, dies at 89 Aerial footage shows extensive Helene ...
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...
Abbvie Inc. failed to defeat a proposed class action by a Chicago-area technician who says he and other workers were ...
Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...
AbbVie Inc. closed $6.44 short of its 52-week high ($199.95), which the company achieved on September 3rd.
1d
AbbVie (ABBV) announced submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for accelerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback